These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 12201487)

  • 21. Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma.
    Myoung H; Hong SD; Kim YY; Hong SP; Kim MJ
    Cancer Lett; 2001 Feb; 163(2):191-200. PubMed ID: 11165754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
    Rosanò L; Spinella F; Salani D; Di Castro V; Venuti A; Nicotra MR; Natali PG; Bagnato A
    Cancer Res; 2003 May; 63(10):2447-53. PubMed ID: 12750265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
    Zhang L; Lau YK; Xia W; Hortobagyi GN; Hung MC
    Clin Cancer Res; 1999 Feb; 5(2):343-53. PubMed ID: 10037184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer.
    Devalapally H; Duan Z; Seiden MV; Amiji MM
    Int J Cancer; 2007 Oct; 121(8):1830-8. PubMed ID: 17557285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials.
    Shalinsky DR; Brekken J; Zou H; McDermott CD; Forsyth P; Edwards D; Margosiak S; Bender S; Truitt G; Wood A; Varki NM; Appelt K
    Ann N Y Acad Sci; 1999 Jun; 878():236-70. PubMed ID: 10415735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
    Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
    Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts.
    Auzenne E; Ghosh SC; Khodadadian M; Rivera B; Farquhar D; Price RE; Ravoori M; Kundra V; Freedman RS; Klostergaard J
    Neoplasia; 2007 Jun; 9(6):479-86. PubMed ID: 17603630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
    Polizzi D; Pratesi G; Tortoreto M; Supino R; Riva A; Bombardelli E; Zunino F
    Cancer Res; 1999 Mar; 59(5):1036-40. PubMed ID: 10070960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel.
    Chou TC; Zhang XG; Harris CR; Kuduk SD; Balog A; Savin KA; Bertino JR; Danishefsky SJ
    Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15798-802. PubMed ID: 9861050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paclitaxel and carboplatin for advanced breast cancer.
    Perez EA; Hartmann LC
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):41-5. PubMed ID: 8893899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. YM-231146, a novel orally bioavailable inhibitor of vascular endothelial growth factor receptor-2, is effective against paclitaxel resistant tumors.
    Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
    Biol Pharm Bull; 2005 Nov; 28(11):2096-101. PubMed ID: 16272696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
    Tong L; Chen W; Wu J; Li H
    Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor-suppressing effect of bartogenic acid in ovarian (SKOV-3) xenograft mouse model.
    Dubey VK; Budhauliya A; Jaggi M; Singh AT; Rajput SK
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Aug; 394(8):1815-1826. PubMed ID: 34255109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice.
    Kubota T; Matsuzaki SW; Hoshiya Y; Watanabe M; Kitajima M; Asanuma F; Yamada Y; Koh JI
    J Surg Oncol; 1997 Feb; 64(2):115-21. PubMed ID: 9047247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer.
    Tsujioka H; Fukami T; Yotsumoto F; Ueda T; Hikita S; Takahashi Y; Kondo H; Kuroki M; Miyamoto S
    Anticancer Res; 2011 Jul; 31(7):2461-5. PubMed ID: 21873160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.
    Sharma A; Straubinger RM; Ojima I; Bernacki RJ
    J Pharm Sci; 1995 Dec; 84(12):1400-4. PubMed ID: 8748320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic potential of paclitaxel-radiation treatment of a murine ovarian carcinoma.
    Milas L; Saito Y; Hunter N; Milross CG; Mason KA
    Radiother Oncol; 1996 Aug; 40(2):163-70. PubMed ID: 8884971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.
    Buchsbaum DJ; Zhou T; Grizzle WE; Oliver PG; Hammond CJ; Zhang S; Carpenter M; LoBuglio AF
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3731-41. PubMed ID: 14506165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts.
    Nicoletti MI; Lucchini V; D'Incalci M; Giavazzi R
    Eur J Cancer; 1994; 30A(5):691-6. PubMed ID: 7915909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.